Savara (SVRA) Stock Forecast & Price Target

Savara is in an advantageous position with a clear regulatory path for Molbreevi's approval, positive interactions with the FDA, and a successful resubmission of the BLA with Fujifilm Diosynth Biotechnologies as the drug substance manufacturer, highlighting a strong CMC package. The increase in confirmed aPAP patients to ~5,500 and a larger, better-defined patient population, coupled with Molbreevi's broad efficacy and DLCO% as a clinically-meaningful endpoint, contribute to a favorable outlook for Savara. Additionally, with a recent $149.5 million equity financing and a $75 million royalty funding agreement, Savara has ample financial resources to support the launch of Molbreevi.

Savara is facing several challenges, including a weak market potential with only one product candidate in Phase 3 development, limited market competition, and uncertain approval timeline, projected for August 2026. Despite the potential $1B opportunity for MOLBREEVI in aPAP, the company has yet to secure approval, and recent claims data show only a limited pool of potential patients, leading to a negative outlook on Savara's financial prospects. The company's stock may continue to struggle in the short term due to these factors.